Istituto Di Ricerche Farmacologiche Mario Negri — Clinical Trial Site

21 Registered trials

11 Currently recruiting

Organisation

Istituto Di Ricerche Farmacologiche Mario Negri

Location

Ranica, Italy

Identifier

ORG-100006092

Address

Via Mario Negri 2, 20156, Italy

Departments

#2091:Centro Ricerche cliniche per malattie rare Aldo e Cele Daccò
#3001: Centro ricerche cliniche per Malattie rare Aldo e Cele Daccò
#5001:U.O. Malattie Renali
2501:Centro Ricerche Cliniche per Malattie Rare Aldo e Cele Dacco
3121: Centro Ricerche Cliniche per Malattie Rare Aldo e Cele Daccò
3601: Centro Ricerche Cliniche per Malattie Rare Aldo e Cele Daccò
Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò dell'Istituto Mario Negri
Dipartimento di Ricerca Medicina Renale
Laboratorio di Fasi Avanzate dello Sviluppo dei Farmaci nell'Uomo
Nefrologia e Dialisi Pediatrica - Clinica Pediatrica De Marchi
Nefrology
Oncology
Renal Diseases Department
Renal Medicine
Renal Medicine Department
Ricerca Malattie Rare
UOC Malattie Renali
UOC Malattie Renali - Centro Clinico Aldo e Cele Daccò

Clinical trials at this site (21)

Search interface

A study to assess the effects of zigakibart on IgA nephropathy. Recruiting

2024-519699-24-00 IgA nephropathy 4 2026-04-23
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease Recruiting

2025-521752-26-00 Complement-Mediated Kidney Disease 4 2026-04-22
Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting

2023-509331-83-00 complement 3 glomerulopathy 5 2021-07-28
Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm… Recruiting

2025-523306-33-00 Idiopathic Nephrotic Syndrome 4 2026-03-12
Atacicept in Multiple Glomerular Diseases Recruiting

2024-518465-10-00 Multiple Autoimmune Glomerular Diseases 4 2025-12-12
Phase 2a Study of ALXN1920 in PMN Recruiting

2025-520780-40-00 Primary Mebranous Nephropathy (PMN) 4 2025-11-26
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 IgA nephropathy 5 2025-11-12
A multicenter, single-arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody treatment to iptacopan treatm… Recruiting

2023-504550-35-00 Atypical Hemolytic Uremic Syndrome (aHUS) 5 2025-04-03
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting

2022-502160-20-00 Idiopathic Immune Complex Mediated Membranoproliferativ 5 2023-10-02
Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri… Recruiting

2024-516649-38-00 Recurrent ovarian, fallopian tube or primary peritoneal 5 2020-12-01
Long-term efficacy, safety and tolerability of LNP023 in C3G or IC-MPGN Recruiting

2023-509343-27-00 C3 Glomerulopathy or idiopathic immune-complex membrano 11 2019-10-28
A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended

2024-518457-42-00 chronic kidney disease 4 2025-08-28
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifer… Ended

2023-504625-39-00 C3 glomerulopathy (C3G) or immune complex membranoproli 5 2023-05-18
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 5 2019-02-01
A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dial… Ended

2023-503984-41-00 Hyyperkalemia in CKD stage IIIB to V patients 5 2023-08-02
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patient… Ended

2024-514130-20-00 complement 3 glomerulopathy (C3G)/immune complex membr 5 2022-04-04
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplan… Ended

2024-511544-36-00 complement 3 glomerulopathy (C3G)/immune complex membra 4 2021-12-21
Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrom… Ended

2024-515857-93-00 Primary Membranous Nephropathy 4 2021-12-17
Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Th… Ended

2024-513744-28-00 Membranous nephropathy 4 2021-10-22
A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease Ended

2023-506897-11-00 Non-diabetic chronic kidney disease 5 2021-10-18
Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended

2024-511067-29-00 IgA Nephropathy 5 2021-01-25